Leaving the study early · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with sulpiride (very low certainty).
1 finding from 1 review
General functioning: Average endpoint general functioning score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Global state: Average endpoint global state score (clinically improved) (CGI ‐ unchanged/worse) · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes global state: Average endpoint global state score (clinically… compared with thiothixene (very low certainty).
1 finding from 1 review
Adverse effects: Clinically important general adverse effect (no data) · schizophrenia
1 finding from 1 review
Death: Suicide and natural causes (no data) · schizophrenia
1 finding from 1 review
Length of hospital stay · schizophrenia
1 finding from 1 review
Mental state: Average endpoint general mental state score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Leaving the study early · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with thiothixene (very low certainty).
1 finding from 1 review
General functioning: Average endpoint general functioning score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Global state: Average endpoint global state score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Adverse effects: Clinically important general adverse effect (no data) · schizophrenia
1 finding from 1 review
Death: Suicide and natural causes (no data) · schizophrenia
1 finding from 1 review
Length of hospital stay · schizophrenia
1 finding from 1 review
Mental state: Average endpoint general mental state score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Leaving the study early · schizophrenia
1 finding from 1 review
General functioning: Average endpoint general functioning score (clinically improved) (no data) · patients with schizophrenia
1 finding from 1 review
General functioning: Average endpoint general functioning score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Global state: Average endpoint global state score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Adverse effects: Clinically important general adverse effect (EPSEs) · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes adverse effects: Clinically important general adverse effect (EPSEs) compared with chlorpromazine (very low certainty).
1 finding from 1 review
Clinically significant response on global state · patients with schizophrenia
It is very uncertain whether ZUCLOPENTHIXOL DIHYDROCHLORIDE changes clinically significant response on global state ‐ as defined by each… compared with PLACEBO (very low certainty).
1 finding from 1 review